Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 October 2025
Suspected Cancer: recognition and referral (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 13 March 2026
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after chemotherapy ID3753Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2026
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC